In last trading session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw 0.72 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $5.67 trading at $0.13 or 2.35% at ring of the bell on the day assigns it a market valuation of $387.70M. That closing price of PHAT’s stock is at a discount of -247.62% from its 52-week high price of $19.71 and is indicating a premium of 8.11% from its 52-week low price of $5.21.

For Phathom Pharmaceuticals Inc (PHAT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 10 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.08 in the current quarter.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information

Upright in the green during last session for gaining 2.35%, in the last five days PHAT remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $5.67 price level, adding 8.7% to its value on the day. Phathom Pharmaceuticals Inc’s shares saw a change of -30.17% in year-to-date performance and have moved 0.89% in past 5-day. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) showed a performance of -18.88% in past 30-days.

Wall Street analysts have assigned a consensus price target of 27 to the stock, which implies a rise of 79.0% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -111.64% in reaching the projected high whereas dropping to the targeted low would mean a loss of -111.64% for stock’s current value.

Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts

This year revenue growth is estimated to rise 7,414.06% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 25.65M for the same. And 4 analysts are in estimates of company making revenue of 28.54M in the next quarter. Company posted 682k and 1.91M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -34.71% while estimates for its earnings growth in next 5 years are of 22.16%.

Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders

FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the top institutional holder at PHAT for having 10.11 million shares of worth $104.13 million. And as of 2024-06-30, it was holding 17.2637 of the company’s outstanding shares.

The second largest institutional holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, which was holding about 7.46 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.7473 of outstanding shares, having a total worth of $76.89 million.

On the other hand, Invesco Global Fund and PGIM Jennison Health Sciences Fd are the top two Mutual Funds which own company’s shares. As of Oct 31, 2024 , the former fund manager was holding 1.98 shares of worth $11.2 million or 2.89% of the total outstanding shares. The later fund manager was in possession of 1.78 shares on Nov 30, 2024 , making its stake of worth around $10.1 million in the company or a holder of 2.61% of company’s stock.